F-1/A: Polyrizon Ltd. Files Amendment No. 1 to Form F-1, Outlines Resale of 2,419,724 Ordinary Shares

Polyrizon Ltd. has filed an amendment to its Form F-1 registration statement, detailing the resale of up to 2,419,724 ordinary shares by selling shareholders.

Summary

• Polyrizon Ltd., a development stage biotech company, has filed Amendment No. 1 to its Form F-1 registration statement.
• The filing pertains to the resale of up to 2,419,724 ordinary shares by selling shareholders, including shares issuable upon exercise of warrants.
• Polyrizon will not receive any proceeds from the sale of these shares by the selling shareholders.
• However, Polyrizon may receive approximately $9 million if all warrants are exercised for cash.
• The company's ordinary shares are listed on the Nasdaq Capital Market under the symbol PLRZ.
• Polyrizon is an emerging growth company and a foreign private issuer, subject to reduced reporting requirements.
• The company is developing medical device hydrogels delivered as nasal sprays, targeting viruses and allergens.
• Key product candidates include PL-14 (nasal allergies blocker), PL-15 (COVID-19 blocker), and PL-16 (influenza blocker).
• The company is also developing Trap and Target (T&T) product candidates for nasal delivery of active pharmaceutical ingredients.
• The company expects PL-14 to be regulated as a Class II medical device under the 510(k) pathway, with preclinical safety trials scheduled for Q2 2025 and pivotal clinical trials in Q4 2025.
• PL-15 and PL-16 are expected to be regulated as Class II medical devices under a De Novo Classification request, with preclinical safety trials scheduled for Q2 2025 and feasibility clinical trials planned for 2026 and 2027, subject to additional financing.
• The company has entered into a license agreement with SciSparc Ltd. for the SCI-160 platform to develop pain treatments.
• The company has a collaboration agreement with NurExone Biologic Inc. to develop an intranasal delivery system for spinal cord injuries.
• The company has undertaken several recent financings, including convertible loan agreements and securities purchase agreements.
• The company closed its initial public offering (IPO) on October 30, 2024, raising approximately $4.2 million.
• The company signed a manufacturing agreement with Eurofins CDMO Amatsiaquitaine S.A.S for PL-14 clinical trial material.
• The company appointed Asaf Azulay as VP of Regulatory Affairs and Quality Assurance and Dr. Michal Meir as Senior Director of Regulatory and Clinical Affairs.
• The company faces risks related to financial condition, product development, reliance on third parties, intellectual property, and operations in Israel.

Sentiment

Score: 5

Explanation: The document presents a balanced view, highlighting both the potential of the company's technology and the risks associated with its business. The company's financial situation and dependence on future funding are significant concerns.

Positives

• The company has a diverse pipeline of product candidates targeting significant market opportunities.
• The company has established collaborations and partnerships to support its research and development efforts.
• The company has a experienced management team and scientific advisory board.
• The company has secured funding through its IPO and other financing activities.
• The company is pursuing regulatory pathways for its product candidates.

Negatives

• The company has incurred significant losses since its inception and expects to continue to incur losses for the foreseeable future.
• The company is dependent on the success of its C&C product candidates.
• The company may need to raise substantial additional funding, which may not be available on acceptable terms, or at all.
• The company has not previously conducted pivotal clinical trials.
• The company relies on third parties to manufacture the raw materials that it uses to create its product candidates.

Risks

• The company's financial condition and capital requirements pose a risk to its ability to continue as a going concern.
• The company's product development and clinical testing efforts are subject to numerous risks and uncertainties.
• The company's reliance on third parties for manufacturing and clinical trials poses a risk to its ability to obtain regulatory approval and commercialize its product candidates.
• The company's intellectual property rights may not be adequately protected.
• The company's operations in Israel are subject to political, economic, and military instability.
• The company may be subject to U.S. federal and state healthcare fraud and abuse laws, false claims laws, physician payment transparency laws and health information privacy and security laws.

Future Outlook

The company expects expenses and operating losses to increase as it continues clinical development of its C&C product candidates and develops other product candidates using its T&T platform technology.

Industry Context

The company operates in the competitive medical device and pharmaceutical industry, facing competition from major multinational companies and other research organizations.

Comparison to Industry Standards

• The FDA submission and clearance process for Alzair, Nasalease, and Bentrio, predicate devices for Polyrizon's PL-14 product candidate, took 86 and 140 days, respectively.
• The company intends to follow home country governance practices as a foreign private issuer, which may provide less protection to investors compared to U.S. domestic issuers.

Management Changes

Related Party Transactions

• The company has entered into various transactions with related parties, including private placements of securities and convertible loan agreements.
• One of the former directors, Liron Carmel, is the Chief Executive Officer of XYLO.

Stakeholder Impact

• Shareholders may experience dilution from future equity issuances.
• The company's success depends on its ability to attract and retain qualified personnel.
• The company's operations are subject to risks related to political, economic, and military instability in Israel.

Next Steps

• Initiate preclinical safety trials for PL-14, PL-15, and PL-16 in Q2 2025.
• Commence pivotal clinical trial for PL-14 in Q4 2025.
• Submit a 510(k) application for PL-14 to the FDA.
• Initiate feasibility clinical trials for PL-15 and PL-16 in 2026 and 2027, subject to additional financing.
• Submit De Novo Classification requests for PL-15 and PL-16 to the FDA.
• Conduct feasibility studies for T&T platform product candidates with corticosteroids, benzodiazepines and naloxone, beginning in the fourth quarter of 2024 through the first quarter of 2026.
• Begin pre-clinical studies for T&T platform product candidates in the second quarter of 2026.
• Plan Phase I clinical trials for the leading T&T technology product candidate for the fourth quarter of 2027, subject to securing additional financing.
• Start initial testing to explore the potential of SCI-160 platform when combined with the T&T technology, in the first quarter of 2025.

Key Dates

Keywords

Polyrizon, ordinary shares, resale, warrants, clinical trials, medical device, nasal spray, hydrogel, SciSparc, NurExone, IPO, financing, PL-14, PL-15, PL-16, Trap and Target, COVID-19, influenza, allergies